Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CD274 | Q9NZQ7 | 10/20 | 0.50 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.44 |
| ▸ | PDE4A | P27815 | 1/20 | 0.44 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.44 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | SIK1 | P57059 | 2/20 | 0.42 |
| ▸ | SIK2 | Q9H0K1 | 2/20 | 0.42 |
| ▸ | SIK3 | Q9Y2K2 | 2/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5473560 | 0.96 | CYP2D6 (0.50) | CD274PDE4BPDE4APDE4CPDE4D | |
| SCHEMBL5476471 | 0.95 | CD274 (0.53) | CD274PDE4BPDE4APDE4CPDE4D | |
| SCHEMBL5477803 | 0.91 | CYP2D6 (0.55) | CD274PDE4BPDE4APDE4CPDE4D | |
| SCHEMBL5473388 | 0.89 | PDE4D (0.45) | CD274PDE4BPDE4APDE4CPDE4D | |
| SCHEMBL5056713 | 0.85 | CD274 (0.55) | CD274PDE4BPDE4APDE4CPDE4D | |
| SCHEMBL5479681 | 0.84 | PDE4D (0.43) | PDE4BPDE4APDE4CPDE4DCYP2C9 | |
| SCHEMBL5479033 | 0.84 | PDE4D (0.43) | PDE4BPDE4APDE4CPDE4DCYP2C9 | |
| SCHEMBL5477776 | 0.84 | PDE4D (0.43) | PDE4BPDE4APDE4CPDE4DCYP2C9 | |
| SCHEMBL5480188 | 0.83 | PDE4D (0.47) | PDE4BPDE4APDE4CPDE4DHPGD | |
| SCHEMBL5476457 | 0.82 | PDE4D (0.42) | PDE4BPDE4APDE4CPDE4DHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070185149-A1 | Novel amido-substituted hydroxy-6-phenylphenanthridines and their use as pde4 inhibtors | ALTANA PHARMA AG (DE) | 2007-08-09 | — | — | US | claimed |
| US-20070185149-A1 | Novel amido-substituted hydroxy-6-phenylphenanthridines and their use as pde4 inhibtors | ALTANA PHARMA AG (DE) | 2007-08-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070185149-A1 | Novel amido-substituted hydroxy-6-phenylphenanthridines and their use as pde4 inhibtors | PDE4A, PDE4B, PDE4C | CD274 1966/4885PDE4B 2/4885PDE4A 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.